Kornimate/medical-research-clean huggingface dataset:
cora-q15: continuous vs. single-injection interscalene block on qor-15 in outpatient rotator cuff surgery

Conditions: Arthropathy Shoulder; Pain, Acute; Anesthesia

Summary: the purpose of the study will be to compare the efficacy of single-injection interscalene block versus continuous interscalene block on the quality of recovery in patients undergoing outpatient arthroscopic rotator cuff repair surgery. the participants will: * be randomized to receive either a single-injection interscalene block or continuous infusion via an elastomeric pump. * be monitored via telephone by the research team to complete the qor-15 survey, assess pain levels, the need for tramadol use, and any complications. * have follow-up by the acute pain unit during the first 3 days.

after obtaining approval from the institutional cec-ccss and prospective registration of the study at clinicaltrials.org, the investigators will recruit patients who meet the inclusion criteria and provide written consent. following surgery and placement of the interscalene block with a catheter, in the recovery unit, participants will be assigned to one of two groups according to a random number table, in a 1:1 ratio using block randomization (block sizes of 4, 6, and 8) through sealed envelopes.

Eligibility criteria:
inclusion criteria: * adults (≥18 years, \< 75 years) scheduled for elective outpatient arthroscopic rotator cuff repair surgery. * patients capable of managing a continuous outpatient regional analgesia system based on an interscalene block (eligibility criteria: able to understand verbal and written instructions, have home support, and live geographically close to the healthcare center). * willing and able to provide informed, written consent to participate in the study. exclusion criteria: * history of chronic opioid use (\>3 months). * severe comorbidities (e.g., renal or hepatic failure, asa classification of 3 or higher). * allergy to local anesthetics, dexamethasone, or the analgesic drugs used in the study. * patients with contraindications for peripheral nerve block.

Keywords: ambulatory surgery rotator cuff repair regional anesthesia
oral motor intervention for preterm babies

Conditions: Preterm Babies

Summary: the goal of this clinical trial is to evaluate the effect of oral motor intervention (piomi) applied to preterm babies along with the smell and taste of breast milk on feeding parameters and the transition time to oral feeding. the main questions it aims to answer are: * does affect nutritional parameters piomi with the smell of breast milk? * does affect nutritional parameters piomi with breast milk taste? participants will consist of breast milk-scented piomi, breast milk-tasting piomi and control groups. researchers will compare breast milk-scented piomi, breast milk-tasting piomi and control groups to see if early feeding skills.

the preterm newborn population is potentially unable to be fed orally for a long time during the postnatal period. since the physiological functions of preterm babies have not yet matured, their adaptation to the external uterine environment is more complicated. this also means long hospital stays for premature babies. one of the main criteria for a preterm baby to be discharged from the hospital is to be able to feed orally. premature oral motor intervention (piomi) is included in the literature as one of the treatment programs to improve the oral motor control and neurobehavioral status of preterm babies. no study design has been found regarding piomi, which is applied to preterm babies with the smell and taste of breast milk. this research was planned to evaluate the effect of oral motor intervention (piomi) applied to preterm babies along with the smell and taste of breast milk on feeding parameters.

Eligibility criteria:
inclusion criteria: * breastfed, * preterm babies with a gestational age of 28-32 weeks, * no facial deformity, * no respiratory, cardiovascular, gastrointestinal or neurological disorders or syndromes that would prevent or complicate oral feeding, * it will produce preterm babies who are not fed orally but are fed via tube (orogastric). exclusion criteria: * having respiratory distress, * babies who do not receive informed consent form from the parents will not be included.

Keywords: premature infant oral motor intervention (piomi) premature nutrition
measurement of neonatal microvascular hemodynamics using non-invasive optical technologies

Conditions: Infant, Premature, Diseases

Summary: alterations to microvascular blood flow in premature infants, are known to contribute to several major disease entities. the optically-measured tissue blood flow, to determine tissue perfusion that can be use to detect blood loss.

the researchers want to use optical technologies to non-invasively detect blood flow that can tell the onset of blood loss. the research can measure blood flow in stable premature infants in the neonatal intensive care unit over the duration of several weeks. the technologies are laser speckle imaging and diffuse optical spectroscopy. laser speckle imaging non-contact imaging technology, is sensitive to blood flow in superficial tissues. diffuse optical spectroscopy, a probe-based contact technology like pulse oximetry, measures hemoglobin concentrations and states deeper below the skin surface.

Eligibility criteria:
inclusion criteria: * premature infants born or transferred to neonatal intensive care unit with a gestational age of 28-35 weeks exclusion criteria: * none premature infants born or transferred to neonatal intensive care unit
shanghai registry of acute coronary events

Conditions: Coronary Artery Disease; Acute Coronary Syndrome

Summary: srace is an multicenter observational database of outcomes for patients who are hospitalized with an acute coronary events. srace includes over 20 hospitals in shanghai china that have enrolled a total of more than 3,000 patients since 2005, with an annual enrollment of 500 patients. the major purpose of the srace program is to evaluate the prognosis of patients admitted to the hospital due to acute coronary events, comparing different therapeutic strategies, in-hospital transferring system, and so on. all participating physicians receive confidential quarterly reports showing ther outcomes side-by-side with the aggregate outcomes of all participating hospitals.

consecutive patients with stemi who presented symptoms within 12 hours and treated by primary pci in shanghai, were enrolled in the prospective sysytem. several strategies were applied in these patients, including physician vs. patient transfer strategy, upsteam vs. downstream strategy, firebird stent vs. excel stent (bio-absorbable ses), etc. once the patient was randomized to one of these study, he will be denied to the others. clinical and angiographic outcomes were compared, with the final purpose to find an optimal strategy in treating ami patients.

Eligibility criteria:
inclusion criteria: * patients admitted to the hospital with acute coronary syndrome and received medical or interventional treatment exclusion criteria: * non acs patients; * complicated with other lethal disease * predicted life span less than 12 months * known allergy history to any anti-platelet or anti-thrombin medicine * unconscious at the time of arrival at the hospital

Keywords: coronary angioplasty
qualitative and quantitative evaluation of anosmia over time in clinically symptomatic patients tested for covid-19 infection

Conditions: COVID-19

Summary: loss of sense of smell and taste has been anecdotally reported during the covid-19 epidemic. the study investigators wanted to describe the prevalence of olfactory and gustatory dysfunction and assess the factors associated with positive sars-cov-2 infection.


Eligibility criteria:
inclusion criteria: * patients presenting with covid-19 related symptoms including: fever, persistent cough, fatigue, shortness of breath, diarrhoea, abdominal pain, chest pain, sore throat, loss of smell or taste * subjects in prolonged contact with covid-19 infected patients. exclusion criteria: * patients directly admitted to the intensive care unit were excluded * patients opposing use of their health data

Keywords: anosmia sars-cov-2
introducing rapid diagnostic tests into the private health sector

Conditions: Fever; Malaria; Diagnosis; Referral

Summary: most malaria deaths occur within 48 hours of onset of symptoms, and in rural areas with poor access to health facilities, home management of malaria (hmm) can improve the timeliness of treatment and reduce malaria mortality by up to 50%. in order to maximize both coverage and impact, artemisinin combination therapies (acts) should be deployed in hmm programmes, as well as in formal health facilities. up to 80% of malaria cases are treated outside the formal health sector and shops are frequently visited as the first (and in some cases only) source of treatment. strategies to deploy acts in africa thus also need to examine the role of shops in home management and to ensure that drugs sold are appropriate. the current practice of presumptive treatment of any febrile illness as malaria (both at health facilities and in the context of hmm) based solely on clinical symptoms without routine laboratory confirmation, results in significant over-use of antimalarial drugs. with act being a more costly regimen, it is important to be more restrictive in its administration and rapid diagnostic tests (rdts) provide a simple means of confirming malaria diagnosis in remote locations lacking electricity and qualified health staff. this study therefore proposes to evaluate the feasibility, acceptability, and cost-effectiveness of using rdts to improve malaria diagnosis and treatment by ocal drug shops in an area with high malaria transmission.


Eligibility criteria:
inclusion criteria: * patients with fever * uncomplicted malaria exclusion criteria: * complicated malaria * known allergic reactions to lumartem

Keywords: history of fever measured fever appropriate treatment appropriate referral
inflammation and postoperative tramadol analgesia

Conditions: General Surgery

Summary: patients will be admitted in the intensive care unit after major abdominal surgery. all patients will receive 100 mg of tramadol intravenously every 6 hours. pain will be assessed before and half an hour after tramadol administration by verbal numeric rating scale.

to all patients included in the study from the blood sample taken prior to the operation the leukocytes counts, c-reactive protein (crp), procalcitonin (pct) and lactate level will be performed, as well as arterial blood gas analysis. after admission to the intensive care unit, all patients will receive 100 mg of tramadol intravenously every 6 hours. pain will be assessed before and half an hour after tramadol administration by verbal numeric rating scale (nrs). pain score will be compared between patients with and without systemic inflammation. systemic inflammation is defined as fulfilling at least two of the following major criteria: fever \> 38 oc or hypothermia \ 90 beats/minute, pco2 in arterial blood \ 12.000/mm3 or \ 50 mg/l and pct \> 0.5 ng/ml was also considered systemic inflammation.

Eligibility criteria:
inclusion criteria: * elective and emergency open abdominal surgery * icu admission exclusion criteria: * tramadol allergy * surgery performed laparoscopically * age younger of 18 years and older the 90 years

Keywords: postoperative analgesia tramadol intensive care unit
vitamin d replacement using oral thin film (otf) cholecalciferol in patients undergoing hematopoietic stem cell transplantation

Conditions: Vitamin D Deficiency; Hematopoietic Stem Cell Transplantation (HSCT)

Summary: the investigators hypothesize that vitamin d levels can be improved in hematopoietic stem cell transplantation (hsct) recipients not responding or tolerating standard enteral supplementation options by using vitamin d oral thin film (otf) administration.

the purpose of this study is to investigate efficacy of oral thin film (otf) cholecalciferol (vitamin d3) replacement in hematopoietic stem cell transplantation (hsct) recipients who failed to achieve or sustain adequate vitamin d levels after vitamin d supplementation using current standard of care, or those unable to take/tolerate currently available enteral vitamin d formulations. with oral thin film (otf) cholecalciferol, investigators hope to significantly improve the ease of administration, restoring compliance and facilitating therapeutic vitamin d levels without relying on the gut for absorption.

Eligibility criteria:
inclusion criteria: * hsct recipients of any age with vitamin d levels ≤35 ng/ml, or unable to tolerate, or refractory to enteral supplementation formulations of vitamin d will be offered vitamin d otf. exclusion criteria: * subjects with 25ohd level \>60ng/ml. subjects can be re-screened multiple times and enrolled later if they meet study criteria. * subjects with clinically significant and uncontrolled hypercalcemia as deemed by treating physician.
optimizing provider training in eating disorders (opted)

Conditions: Anorexia Nervosa; Atypical Anorexia Nervosa

Summary: this is a randomized controlled trial for mental health clinicians comparing two methods of training in family-based treatment (fbt) for restrictive eating disorders.

this is a randomized controlled trial for mental health clinicians comparing two methods of training in family-based treatment (fbt) for restrictive eating disorders. clinicians who treat youth and accept medicaid insurance within a predetermined group of participating california counties will be randomized to receive either web-based training (wbt) or live two-day training in fbt. data will be collected on the feasibility, acceptability, appropriateness, and effectiveness of the training (web-based vs. live). following training, a subset of clinicians may opt into group consultation for one year. consultation groups will be kept separate by training condition. data will also be collected from clinicians on the extent to which they perceive the treatment itself (i.e., fbt) as feasible, acceptable, and appropriate for medicaid-insured youth. in addition to implementation outcomes, de-identified clinical data will be collected from providers about their cases up to one year following the initial training.

Eligibility criteria:
inclusion criteria: * mental health provider licensed to practice in the state of california, or unlicensed mental health providers in california who are formally employed by their agency/clinic and have a licensed clinical supervisor who agrees to take legal responsibility for any cases treated with fbt * must treat patients with medicaid insurance in a participating county exclusion criteria: - students (practicum students, interns, externs) or other learners

Keywords: training eating disorders family based treatment medicaid community mental health children and adolescents mental health clinicians
a study to evaluate sapablursen (formerly isis 702843, ionis-tmprss6-lrx) in patients with polycythemia vera

Conditions: Phlebotomy Dependent Polycythemia Vera

Summary: the main purpose of this study is to evaluate the efficacy of sapablursen in reducing the frequency of phlebotomy and in improving quality of life assessments in participants with polycythemia vera.

this is a phase 2a, multi-center, randomized, open-label study of sapablursen in up to 40 participants with pd-pv. the study consists of 4 periods: 1) screening period: up to 7 weeks; 2) treatment period: 37 weeks 3) treatment extension period: 36 weeks; 4) post-treatment period: 13 weeks. in the treatment period, study drug is given by subcutaneous (under the skin) injection(s). there will be a total of 9 doses given over about 8 months. in the treatment extension period, there will be a total of 9 doses given over about 8 months. participants will be assigned to receive one of 2 dosing levels - a higher or a lower level, with an equal chance of being assigned to either dosing level. all participants will receive study drug; there is no placebo. this study was extended to allow participants to receive sapablursen for an additional 36 weeks following the initial 37-week treatment period.

Eligibility criteria:
inclusion criteria 1. meet modified world health organization (who) 2016 diagnostic criteria for polycythemia vera (pv) at the time of clinical diagnosis 2. participant must be phlebotomy dependent. 3. participants do not need to be on cytoreductive therapy and do not need to have been previously treated with cytoreductive therapy. if the patient was previously on cytoreductive therapy it must have been discontinued at least 3 months prior to screening, with all associated aes resolved. if the patient is currently on cytoreductive therapy they must be on a stable dose of hydroxyurea, recombinant or pegylated interferon, or ruxolitinib for at least 3 months prior to screening. exclusion criteria 1. meets criteria for post-polycythemia vera myelofibrosis (ppv-mf) as defined by the international working group- myeloproliferative neoplasms research and treatment (iwg-mrt) 2. moderate to severe splenic pain or spleen-related organ obstruction 3. active or chronic bleeding within 1 month of screening, significant concurrent/recent coagulopathy, history of immune thrombocytopenic purpura (itp) 4. known primary or secondary immunodeficiency 5. active infection with human immunodeficiency virus (hiv), hepatitis c, or hepatitis b. 6. active infection requiring systemic antiviral or antimicrobial therapy or active novel coronavirus disease (covid-19) infection 7. malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or non-metastatic prostate cancer that has been successfully treated 8. surgery requiring general anesthesia within 1 month prior to screening

Keywords: polycythemia vera
the predict study: prospective early detection in a population at high-risk for common malignant tumor

Conditions: Early Detection of Cancer

Summary: this is a observational, multicenter study, monitoring the circulating tumor dna (ctdna) in people who is at risk of cancers，assessing the sensitivity and specificity of ctdna detection in early screening of pan-carcinoma.

2000 patients with positive tumor protein markers or cancer screening were recruited. all patients were tested for ctdna at enrollment and followed up at 6 months and 1 year. the study was completed at the time of cancer diagnosis or the longest follow-up time (1 year).

Eligibility criteria:
inclusion criteria: 1. patients aged at or over 45 years old. 2. patients who with one or more of the following situations: 1. in afp (\>20ug/l), ca125 (\>70u/ml), cea (\>7ng/ml) and ca199 (\>60u/ml), more than one item was abnormal for two consecutive times within one month. 2. patients with viral hepatitis (hepatitis b / c surface antigen positive with liver function damage. 3. patients with liver nodules detected by ultrasound and hemangioma excluded. 4. patients with compensated cirrhosis. 5. ca125\>35u/ml and he4 was abnormal (the reference value of he4 in premenopausal and postmenopausal women was 68.96 pmol/l and 114.90 pmol/l respectively). 6. patients with ovarian masses found by ultrasonography (premenopausal \> 5cm, postmenopausal \> 3.5cm). 7. patients with pancreatic space-occupying found by ultrasonography. 8. patients with bi-rads grade 4 or above by ultrasound or mammography. 9. ca125\>35u/ml and bi-rads above grade 3 by ultrasound or mammography. 10. ca153\>25u/ml and bi-rads above grade 3 by ultrasound or mammography. 11. family genetic history of breast cancer and ovarian cancer, and bi-rads above grade 3 by ultrasound or mammography. 12. patients with a positive fecal occult blood test and haemorrhoids excluded 13. patients with a positive fecal occult blood test and positive cea 14. more than 2 items were abnormal in pgi, pgr and g-17 (criteria: pgi≤70 ug/l, pgr≤7.0, g-17≤1 pmol/l or g-17≥15 pmol/l). 3. ability to collect specimens from each time point and provide corresponding clinical information. 4. understand the research plan and voluntarily participate in the study, sign the informed consent form. exclusion criteria: 1. patients with previous or present cancer. 2. patients with serious diseases, especially those with a survival period of less than 3 years. 3. patients with factors that affect the diagnosis of the disease (such as mri related cardiac pacemakers, ferromagnetic implants, etc.). 4. patients with a known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation. 5. women who are pregnant or preparing for pregnancy. 6. patients who voluntarily withdraw for any reason. 7. patients who cannot complete the research plan

Keywords: pan-cancer cancer screening ctdna
defining the clinical potential of mass response as a biomarker for patient tumor sensitivity to drugs

Conditions: Stage III Breast Cancer; Stage IV Breast Cancer; Stage III Lung Cancer; Stage IV Lung Cancer; AML; Multiple Myeloma in Relapse; Carcinoma; Carcinoma, Pancreatic; Carcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Carcinoma Breast; Carcinoma Prostate; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Neuroendocrine; Carcinoma, Small Cell Lung; Carcinoma, Ovarian; Carcinoma Bladder; Carcinoma of Esophagus; Carcinoma Cervix; Carcinoma, Thymic; Carcinoma, Ductal; Carcinoma of the Head and Neck; Carcinoma of the Lip; Carcinoma of the Oral Cavity; Carcinoma of Unknown Primary; Carcinoma of the Skin; Carcinoma of the Anus; Carcinoma of the Larynx; Carcinoma of the Penis; Carcinoma of the Oropharynx; Carcinoma of the Appendix; Carcinoma of the Paranasal Sinus; Carcinoma of the Vulva; Malignant Pleural Effusion; Malignant Ascites; Mesothelioma; Cholangiocarcinoma

Summary: the primary objective of this study, sponsored by travera in massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from varying cancers and biopsy formats.


Eligibility criteria:
inclusion criteria: * sample collection or biopsy of tumor is clinically indicated as part of soc * prior to preceding onto therapy for treatment exclusion criteria: * unable to obtain sufficient sample